Fundraising FoxGraviton Bioscience
New York, US · Founded 2020 · 2 known investors
Find your way into Graviton Bioscience
Sign up to see every warm intro you have to Graviton Bioscience
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Graviton Bioscience team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Graviton develops immunomodulatory therapies for patients with fibrotic, autoimmune, and central nervous system diseases. The company targets multiple molecular pathways to reduce disease burden and restore biological balance.
Founders & leadership
Graviton Bioscience was founded in 2020 by Samuel Waksal.
Board
Investors · 2
How we know: Innova Capital Partners, LLC's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Pontifax Venture Capital's portfolio page · a partner's Signal profile · board seat on SEC Form D · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$93.3M disclosed across 4 rounds · 2021–2024
▶$25MraisedFeb 2024 · 1 investors · BiotechnologyRule 506(b)
- Samuel D WaksalExecutive Officer, Director, Promoter
- Bihua ChenDirector
- Jeremy LevinDirector
- David MacMillanDirector
- James BoylanDirector
- Stelios PapadopoulosDirector
- Ran NussbaumDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Jan 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$39.8MraisedDec 2023 · 11 investors · BiotechnologyRule 506(b)
- James BoylanDirector
- Bihua ChenDirector
- Samuel D. WaksalExecutive Officer, Director
- Jeremy LevinDirector
- David MacMillanDirector
- Stelios PapadopoulosDirector
- Ran NussbaumDirector
- Offering amount
- $50M
- Amount sold
- $39.8M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$25MraisedDec 2023 · 1 investors · BiotechnologyRule 506(b)
- Jeremy LevinDirector
- Ran NussbaumDirector
- Samuel D. WaksalExecutive Officer, Director
- Bihua ChenDirector
- Stelios PapadopoulosDirector
- James BoylanDirector
- David MacMillanDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$3.5MraisedFeb 2021 · 3 investors · BiotechnologyRule 506(b)
- Steven GordonExecutive Officer, Director
- Richard GirouxDirector
- Samuel WaksalDirector
- Philip BarachDirector
- Offering amount
- $30M
- Amount sold
- $3.5M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Graviton Bioscience do?
- Graviton develops immunomodulatory therapies for patients with fibrotic, autoimmune, and central nervous system diseases. The company targets multiple molecular pathways to reduce disease burden and restore biological balance.
- Who founded Graviton Bioscience?
- Graviton Bioscience was founded by Samuel Waksal in 2020.
- Who are Graviton Bioscience's investors?
- Graviton Bioscience's investors include Innova Capital Partners, LLC, Pontifax Venture Capital.
- How much funding has Graviton Bioscience raised?
- Graviton Bioscience has disclosed $93.3M raised across 4 rounds.
- Where is Graviton Bioscience headquartered?
- Graviton Bioscience is headquartered in New York, US.